<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03445247</url>
  </required_header>
  <id_info>
    <org_study_id>104-7771A</org_study_id>
    <nct_id>NCT03445247</nct_id>
  </id_info>
  <brief_title>Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy</brief_title>
  <official_title>An Investigation on the Effects of Extracorporeal Low-intensity Shockwave Therapy on Protenuria, Renal Function, and Blood Pressure in Type 2 Diabetic Patients in Stage 3-4 Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current study, we use extracorporeal low-intensity shockwave therapy (ESWT) to treat
      on patients with type 2 diabetes in stage 3-4 chronic kidney disease and see whether it can
      improve the proteinuria, renal function, and blood pressure compared to baseline and control
      group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy is the major contributor to end stage renal disease worldwide.
      Extracorporeal shock wave treatments (ESWT) with low-intensity was reported to be beneficial
      in inducing cell regeneration and reducing inflammation and have been successfully used for
      bone fracture, cardiac ischemia, and erectile disorders. In this study, sixty patients with
      stage III &amp; IV (15&lt;=estimated glomerular filtration rate (eGFR)&lt;60 ml/min/1.73m2) will be
      recruited and allocated to control and experimental groups in a 1:1 ratio. In experiment
      group, a total of 1200 shockwaves, with low energy density 0.1mj/mm2 and a frequency of 120
      shocks/min, will be applied per kidney per treatment session. The treatment will be given
      twice a week for 3 consecutive weeks, followed by 3 weeks of recess and an additional series
      of 6 sessions (totally 12 times). Patients in each group will be evaluated with eGFR, urine
      protein-creatinine ration, blood pressure, and biochemistry data at the beginning (index day)
      and 12 months after starting of the therapy. (Outcome time point: 12 months)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes of estimated glomerular filtration rate</measure>
    <time_frame>12 month</time_frame>
    <description>using Modification of Diet in Renal Disease (MDRD) equation, which is eGFR (mL/min/1.73m2) = 175 × serum creatinine−1.154 × age−0.203× 0.742 (if female) to evaluate renal function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>changes of proteinuria</measure>
    <time_frame>12 month</time_frame>
    <description>using spot urine albumin- and protein-creatinine ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of systolic and diastolic blood pressure</measure>
    <time_frame>12 month</time_frame>
    <description>Let patients rest for 15 mins and check blood pressure using same sphygmomanometer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Nephropathy Type 2</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>No intervention, no placebo, but do the same blood tests and examinations as experiment group at the same time points</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extracorporeal low-intensity shockwave group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>with 12 times extracorporeal low intensity shockwave therapy and do the blood test and assessments at baseline, 3, 6, 12 m after initiation of therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Extracorporeal low-intensity shockwave</intervention_name>
    <description>Omnispec device to give a total of 1200 shockwaves, with low energy density at 0.1 mj/mm2 and a frequency of 120 shocks/min per kidney per treatment session, totally 12 times.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Extracorporeal low-intensity shockwave group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 y/o or &lt;80 y/o

          2. Diagnosed as type 2 diabetes.

          3. Baseline HbA1C &lt;7.5%

          4. Baseline glomerular filtration rate (eGFR) ≧15 and &lt;60 ml/min/1.73m2

          5. Baseline urine albumin-to-creatinine ratio (UACR) &gt;30 and &lt;3000 mg/g

          6. Subject receives ACEi or ARB for 3 months before enrollment

          7. Subject is willing to sign the permit and receive 12 times shockwave therapy

        Exclusion Criteria:

          1. Subject is pregnant or breast feeding

          2. Subject has cancer or chronic inflammatory disease

          3. Subject has bleeding tendency, eg thrombocytopenia, PT INR &gt; 2.5

          4. Subject has active urinary tract infection or other active infections

          5. Subject's sBP&gt;160mmHg or dBP&gt;100mmHg

          6. Subject has stroke, cardiac infection or arrhythmia in 6 months before enrollment

          7. Subject has local inflammation or infection over treatment areas

          8. Subject has pacemaker or other metal implants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lung-Chih Li, MD, PhD.</last_name>
    <phone>886-7-7317123</phone>
    <phone_ext>8306</phone_ext>
    <email>longee01@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Chang-Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>Please Select</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lung-Chih Li, MD.PhD</last_name>
      <phone>886-7317123</phone>
      <phone_ext>8306</phone_ext>
      <email>longee01@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Nephropathies</keyword>
  <keyword>Extracorporeal low intensity shockwave therapy</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

